ESTRO 2022 - Abstract Book

S226

Abstract book

ESTRO 2022

Conclusion The phase II target was achieved with early safety data showing acceptable acute toxicity, compliance, and PROs with IMRT dose intensification. Both escalation arms have been taken forward into phase III. Recruitment stands at 262/459 as of 6/10/2021.

OC-0270 Final results of the French national cohort ANABASE : treatment and outcome in anal cancer

V. Vendrely 1 , C. Lemanski 2 , P. Pommier 3 , K. Le Malicot 4 , E. Francois 5 , E. Rivin Del Campo 6 , P. Regnault 7 , N. Baba-Hamed 8 , P. Ronchin 9 , G. Crehange 10 , D. Tougeron 11 , E. Menager-Tabourel 12 , O. Diaz 13 , M. Hummelsberger 14 , A. De La Rochefordiere 15 , C. Lepage 16 , L. Quero 17 1 CHU Bordeaux, Oncology radiotherapy, BORDEAUX, France; 2 Val d'Aurelle Cancer Center, Radiotherapy, Montpellier, France; 3 Léon Bérard Cancer Center, Radiotherapy, LYON, France; 4 Fédération Francophone de Cancérologie Digestive, university of Burgundy, Biostatistics, Dijon, France; 5 Antoine Lacassagne Cancer Center, Oncology, Nice, France; 6 APHP, Tenon Hospital, Radiotherapy, Paris, France; 7 Tivoli Clinic, Radiotherapy, Bordeaux, France; 8 Saint-Joseph Hospital group, Oncology Department, Paris, France; 9 Azuréen Cancer Center, Radiotherapy, Mougins, France; 10 Georges François Leclerc cancer center, radiotherapy, Dijon, France; 11 CHU Poitiers, Medical Oncology, Poitiers, France; 12 Derpartemental Hospital of Vendee, Medical Oncology, La Roche sur Yon, France; 13 Daniel Hollard Institute, Radiotherapy, Grenoble, France;